1. Generics Bulletin
  2. >>Business
  3. >>Deals

Neuraxpharm Brings In Greek Olanzapine Brand

Strikes Deal With Local Firm Lyofin To Expand In Greece With Lazap Antipsychotic

 
• By Dave Wallace

CNS specialist Neuraxpharm has snapped up the Lazap olanzapine brand in Greece from local firm Lyofin, helping to further expand its presence in the Greek market following a recent acquisition.

Magnifying glass with image of Greek flag
Neuraxpharm has identified an opportunity in Greece • Source: Shutterstock

European central nervous system specialist Neuraxpharm has struck a deal to acquire the Lazap olanzapine brand in Greece from local player Lyofin, enabling Neuraxpharm to further expand in the Greek market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.